Susquehanna International Group, LLP Summit Therapeutics Inc. Transaction History
Susquehanna International Group, LLP
- $560 Billion
- Q3 2024
A detailed history of Susquehanna International Group, LLP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 366,395 shares of SMMT stock, worth $6.55 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
366,395
Previous 253,801
44.36%
Holding current value
$6.55 Million
Previous $1.98 Million
305.46%
% of portfolio
0.0%
Previous 0.0%
Shares
15 transactions
Others Institutions Holding SMMT
# of Institutions
192Shares Held
75.8MCall Options Held
2.01MPut Options Held
2.84M-
Baker Bros. Advisors LP New York, NY24.4MShares$436 Million5.73% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.9MShares$196 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$141 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.44MShares$97.2 Million0.01% of portfolio
-
State Street Corp Boston, MA3.47MShares$62 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.6B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...